{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:32:21Z","timestamp":1790065941296,"version":"4.0.1"},"reference-count":55,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Affibody AB, Sweden, and ACELYRIN Inc."}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["mAbs"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/19420862.2023.2209920","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T08:24:33Z","timestamp":1684139073000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":58,"title":["Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis"],"prefix":"10.1080","volume":"15","author":[{"given":"Susanne","family":"Klint","sequence":"first","affiliation":[{"name":"Affibody AB","place":["Solna, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Feldwisch","sequence":"additional","affiliation":[{"name":"Affibody AB","place":["Solna, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindvi","family":"Gudmundsdotter","sequence":"additional","affiliation":[{"name":"Affibody AB","place":["Solna, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Dillner Bergstedt","sequence":"additional","affiliation":[{"name":"Affibody AB","place":["Solna, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin","family":"Gunneriusson","sequence":"additional","affiliation":[{"name":"Affibody AB","place":["Solna, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingmarie","family":"H\u00f6id\u00e9n Guthenberg","sequence":"additional","affiliation":[{"name":"Affibody AB","place":["Solna, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Wennborg","sequence":"additional","affiliation":[{"name":"Affibody AB","place":["Solna, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Nyborg","sequence":"additional","affiliation":[{"name":"ACELYRIN","place":["Agoura Hills, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol P.","family":"Kamboj","sequence":"additional","affiliation":[{"name":"ACELYRIN","place":["Agoura Hills, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Peloso","sequence":"additional","affiliation":[{"name":"ACELYRIN","place":["Agoura Hills, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bejker","sequence":"additional","affiliation":[{"name":"Affibody AB","place":["Solna, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik Y.","family":"Frejd","sequence":"additional","affiliation":[{"name":"Affibody AB","place":["Solna, Sweden"]},{"name":"Uppsala University","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15610"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.5015"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12946"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0514-y"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.59"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-014-2567-9"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2013.815786"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.042"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14075"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.12.033"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.005"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2905"},{"key":"e_1_3_5_14_1","first-page":"311","article-title":"Anti-IL-17 agents for psoriasis: a review of Phase III data","volume":"15","author":"Farahnik B","year":"2016","unstructured":"Farahnik B, Beroukhim K, Nakamura M, Abrouk M, Zhu TH, Singh R, Lee K, Bhutani T, Koo J. Anti-IL-17 agents for psoriasis: a review of Phase III data. J Drugs Dermatol JDD. 2016;15:311\u201316.","journal-title":"J Drugs Dermatol JDD"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1395796"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01682"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08902.x"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2880"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01894"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00440-2"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406223211037846"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220868"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102383"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.1185"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00126-4"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17071"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.04.019"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11102"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.06.020"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.13502"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/605427"},{"key":"e_1_3_5_32_1","volume-title":"All about albumin: biochemistry, genetics, and medical applications","author":"Peters T","year":"1996","unstructured":"Peters T. All about albumin: biochemistry, genetics, and medical applications. San Diego: Academic Press; 1996."},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21827"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.9.4793"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbiotec.2006.09.013"},{"key":"e_1_3_5_36_1","article-title":"Safety and efficacy of subcutaneous ABY-035, a high-affinity IL-17A inhibiting affibody ligand trap, dosed biweekly during 12 weeks in psoriasis patients","author":"Frejd FY","year":"2018","unstructured":"Frejd FY, Klint S, Gudmundsdotter L, H\u00f6id\u00e9n-Guthenberg I, Feldwisch J, Klaar M, Jensen M, Bejker D, Reich K. Safety and efficacy of subcutaneous ABY-035, a high-affinity IL-17A inhibiting affibody ligand trap, dosed biweekly during 12 weeks in psoriasis patients. Abstract 3630, e-poster number P2053, 27th EADV Congress Paris France. 2018.","journal-title":"Abstract 3630, e-poster number P2053, 27th EADV Congress Paris France"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2017.04.007"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0897-772"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2010.04.014"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2017.35"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107925"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S100940"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.1994.0091"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1093266"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2531"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15111365"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594735"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9041227"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2546161"},{"key":"e_1_3_5_50_1","article-title":"Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II randomized, placebo-controlled, double-blinded, dose-finding multicentre study including long-term treatment","author":"Gerdes S","year":"2023","unstructured":"Gerdes S, Staubach P, Dirschka T, Wetzel D, Weirich O, Niesmann J, da Mota R, Rothhaar A, Ardabili M, Vlasitz G, et al. Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II randomized, placebo-controlled, double-blinded, dose-finding multicentre study including long-term treatment. Under Review. 2023.","journal-title":"Under Review"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13065"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.06.038"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00602-z"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.037"},{"key":"e_1_3_5_55_1","volume-title":"S042 - Late-breaking Research: Procedural Session 2. American Academy of Dermatology Annual Meeting","author":"Lu T","year":"2023","unstructured":"Lu T DC-806, an oral IL-17A inhibitor: proof-of-concept in adults with mild-to-moderate psoriasis. In: S042 - Late-breaking Research: Procedural Session 2. American Academy of Dermatology Annual Meeting, March 17-21, New Orleans, LA, USA. 2023."},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-022X(87)90087-X"}],"container-title":["mAbs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/19420862.2023.2209920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T08:15:44Z","timestamp":1753258544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/19420862.2023.2209920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/19420862.2023.2209920"],"URL":"https:\/\/doi.org\/10.1080\/19420862.2023.2209920","relation":{},"ISSN":["1942-0862","1942-0870"],"issn-type":[{"value":"1942-0862","type":"print"},{"value":"1942-0870","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-12-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2209920"}}